“Research has shown that exosomes carry important information about human health, but studying them has proven challenging,” remarked Paul R. B...
Agilent Technologies , a global leader in life sciences, diagnostics, and applied chemical markets, and the University of California San Diego (UC Sa...
Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. have officially announced a definitive agreement for Genmab's acquisition of ProfoundBio in an all-cash dea...
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company specializing in allosteric modulation-based drug development,...
Voydeya (danicopan) has been granted approval in the United States as an add-on therapy for the treatment of extravascular haemolysis (EVH) in adults diagn...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Compr...
Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global ...
-Function Oncology, a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovativ...
Game-changing continuous-batch production of RNA service removes process development and scale-up steps through automation and significantly cuts clinical ...
The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria Malaria is a serious and potentially fatal paras...
Cytiva shines as a model of sustainable principles in the dynamic field of life sciences, where pioneering innovation intersects with societal resp...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company focused on the development of novel antibody the...
Johnson & Johnson has announced the approval of OPSYNVI® by the U.S. Food and Drug Administration (FDA), marking a significant advanc...
Gilles Besin, Ph.D., CSO at Orbital: “Elegen's unique expertise in supplying...IVT-ready synthetic DNA constructs is very attractive ...
© 2025 Biopharma Boardroom. All Rights Reserved.
